Ryeqo is a medicine used in women of reproductive age to treat: * moderate to severe symptoms of uterine fibroids (non\-cancerous growths in the womb); * symptoms of endometriosis (a condition in which tissue similar to the lining of the womb grows elsewhere in the body). For endometriosis, Ryeqo is used for women who have already had treatment for the condition. Ryeqo contains the active substances relugolix, estradiol and norethisterone acetate.
Therapeutic Indication
Ryeqo is indicated in adult women of reproductive age for: \- treatment of moderate to severe symptoms of uterine fibroids, \- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Therapeutic Area (MeSH)
ATC Code
H01CC54
ATC Item
N/A
Pharmacotherapeutic Group
Pituitary and hypothalamic hormones and analogues
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| relugolix | N/A | relugolix |
| norethisterone acetate | N/A | norethisterone acetate |
| estradiol hemihydrate | N/A | estradiol hemihydrate |
EMA Name
Ryeqo
Medicine Name
Ryeqo
Aliases
N/ANo risk management plan link.
